Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
Clinical trial NCT02315612 · COMPLETED
Trial details
- NCT number
- NCT02315612
- Sponsor
- National Cancer Institute (NCI)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-12-12
- Primary completion
- 2019-04-03
- Enrollment
- 134
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.